%0 Journal Article %A Prabhu, Venugopal Vinod %A Prabhu, Vinod %D 2017 %I Begell House %K lung cancer, epidermal growth factor receptor, tyrosine kinase inhibitors, non-small-cell-lung carcinoma, targeted therapy, cell signaling pathways %N 2 %P 151-158 %R 10.1615/JEnvironPatholToxicolOncol.2017018341 %T Epidermal Growth Factor Receptor Tyrosine Kinase: A Potential Target in Treatment of Non-Small-Cell Lung Carcinoma %U https://www.dl.begellhouse.com/journals/0ff459a57a4c08d0,07051ad6449b2804,384ccc9312a55f09.html %V 36 %X Lung cancer is responsible for 1.6 million deaths. Approximately 80%−85% of lung cancers are of the non-small-cell variety, which includes squamous cell carcinoma, adenocarcinoma, and large-cell carcinoma. Knowing the stage of cancer progression is a requisite for determining which management approach−surgery, chemotherapy, radiotherapy, and/or immunotherapy−is optimal. Targeted therapeutic approaches with antiangiogenic monoclonal antibodies or tyrosine kinase inhibitors are one option if tumors harbor oncogene mutations. Another, newer approach is directed against cancer-specific molecules and signaling pathways and thus has more limited nonspecific toxicities. This approach targets the epidermal growth factor receptor (EGFR, HER-1/ErbB1), a receptor tyrosine kinase of the ErbB family, which consists of four closely related receptors: HER-1/ErbB1, HER-2/neu/ErbB2, HER-3/ErbB3, and HER-4/ErbB4. Because EGFR is expressed at high levels on the surface of some cancer cells, it has been recognized as an effective anticancer target. EGFR-targeted therapies include monoclonal antibodies (mAbs) and small-molecule tyrosine kinase inhibitors. Tyrosine kinases are an especially important target because they play an important role in the modulation of growth factor signaling. This review highlights various classes of synthetically derived molecules that have been reported in the last few years as potential EGFR-TK inhibitors (TKIs) and their targeted therapies in NSCLC, along with effective strategies for overcoming EGFR-TKI resistance and efforts to develop a novel potent EGFR-TKI as an efficient target of NSCLC treatment in the foreseeable future. %8 2017-06-20